Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07553572Not ApplicableRecruiting

Remote Monitoring and Symptom Management Digital Application

Role: lead

NCT06665295Not ApplicableRecruiting

THRIVE-CAR-T Digital App

Role: lead

NCT05583149Phase 2Active Not Recruiting

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Role: lead

All 3 trials loaded